2. Search Result
Search Result
Results for "

myeloid progenitor

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

2

Inhibitory Antibodies

2

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-171792
    BMS-986497

    ORM-6151

    		 Transmembrane Glycoprotein Cancer
    BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML) .
    BMS-986497
  • HY-W583212
    Zn(II) Mesoporphyrin IX

    ZnMP

    		 Biochemical Assay Reagents Heme Oxygenase (HO) Inflammation/Immunology
    Zn (II) Mesoporphyrin IX (ZnMP) is a heme oxygenase inhibitor with photochemical substrate activity. Zn (II) Mesoporphyrin IX specifically inhibits the activity of bone marrow heme oxygenase. In vitro, Zn (II) Mesoporphyrin IX inhibits the growth of erythroid and myeloid progenitor cells in rabbit bone marrow, and blocks the rhG-CSF-induced mobilization of these progenitor cells into the peripheral blood, exhibiting toxicity to hematopoietic growth and progenitor cell production in rabbits. Zn (II) Mesoporphyrin IX undergoes irreversible photochemical decomposition conforming to first-order kinetic characteristics when irradiated with UV-B in 95% ethanol solution. Zn (II) Mesoporphyrin IX can be used in hematopoietic regulation research, but its photolability and toxic effects on the hematopoietic system require attention .
    Zn(II) Mesoporphyrin IX
  • HY-153775
    UC-764864

    		E1/E2/E3 Enzyme Apoptosis Cancer
    UC-764864 is a selective UBE2N inhibitor. UC-764864 covalently binds UBE2N catalytic Cys87, blocks ubiquitin-UBE2N thioester formation and polyubiquitin chain synthesis. UC-764864 blocks ubiquitination of innate immune- and inflammatory-related substrates, and induces cell apoptosis. UC-764864 can be used for the research of acute myeloid leukemia .
    UC-764864
  • HY-P990002
    Anti-Mouse CD117/c-Kit Antibody (2B8)

    		c-Kit Inflammation/Immunology Cancer
    Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody, targeting to mouse CD117/c-Kit. Anti-Mouse CD117/c-Kit Antibody (2B8) reacts with mouse c-Kit (also known as CD117), which is expressed on hematopoietic progenitor cells, mast cells, and acute myeloid leukemia (AML) cells. Anti-Mouse CD117/c-Kit Antibody (2B8) can be used for the detection of flow cytometry, immunofluorescence and immunohistochemistry in cancer and inflammation .
    Anti-Mouse CD117/c-Kit Antibody (2B8)
  • HY-10475G
    AM580

    CD336; NSC608001; Ro 40-6055

    		 RAR/RXR Cancer
    AM580 (CD336) (GMP) is AM580= (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist .
    AM580
  • HY-174767
    Human CCL16 mRNA

    		mRNA Inflammation/Immunology
    Human CCL16 mRNA encodes the human C-C motif chemokine ligand 16 (CCL16) protein, a cytokine that displays chemotactic activity for lymphocytes and monocytes but not for neutrophils. CCL16 also shows a potent myelosuppressive activity and suppresses proliferation of myeloid progenitor cells.
    Human CCL16 mRNA
  • HY-117947
    (R)-OR-S1

    		Histone Methyltransferase Cancer
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
    (R)-OR-S1
  • HY-174762
    Human CCL20 mRNA

    		mRNA Inflammation/Immunology
    Human CCL20 mRNA encodes the human C-C motif chemokine ligand 20 (CCL20) protein that displays chemotactic activity for lymphocytes and can repress proliferation of myeloid progenitors.
    Human CCL20 mRNA
  • HY-179354
    AP21998

    		FKBP Cancer
    AP21998 is a Fv (mutant FKBP) domain-selective ligand that binds to a single FKBPv. AP21998 disrupts FKBP-mediated oligomerization, blocks the proliferation of transformed myeloid progenitors and facilitates their terminal myeloid differentiation. AP21998 disrupts aggregates of CAD-hM1 receptor fusion protein, allowing receptors to exit the ER and enter the plasma membrane. AP21998 can be used for cancer research .
    AP21998
  • HY-174645
    Human IL10RA mRNA

    		mRNA Metabolic Disease
    Human IL10RA mRNA encodes the human interleukin 10 receptor subunit alpha (IL10RA) protein, a receptor for interleukin 10. IL10RA been shown to mediate the immunosuppressive signal of interleukin 10, and thus inhibits the synthesis of proinflammatory cytokines. It is also reported to promote survival of progenitor myeloid cells through the insulin receptor substrate-2/PI 3-kinase/AKT pathway.
    Human IL10RA mRNA
  • HY-P9S0124
    Anti-CD33 Antibody (OR000283)

    ORM-6151 Antibody; BMS-986497 Antibody

    		 Cancer
    Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792) .
    Anti-CD33 Antibody (OR000283)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: